Pasithea Therapeutics Corp.

The momentum for this stock is not very good. Pasithea Therapeutics Corp. is not very popular among insiders. Tradey thinks it is not wise to invest in Pasithea Therapeutics Corp..

News

Pasithea Therapeutics completes PAS-004 chronic toxicity studies

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Globe Newswire MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ( Pasithea or the Company ), a clinical-stage biotechnology company developing PAS-004, a next-generation...\n more…

Pasithea Therapeutics appoints Rebecca Brown to Scientific Advisory Board

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Globe Newswire Dr. Brown is a world-leading expert in Neurofibromatosis (NF) and the Director of the Neurofibromatosis clinic at The Mount Sinai Hospital, NYMIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Pasithea...\n more…

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ( Pasithea or the Company ) a clinical-stage biotechnology company developing...\n more…

Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Up 182.1% in August

Ticker Report Pasithea Therapeutics Corp. (NASDAQ:KTTA - Get Free Report) saw a significant increase in short interest in August. As of August 15th, there was short interest totalling 7,900 shares, an increase of...\n more…